Study to Evaluate the Effects of MBX-8025 in Patients With HoFH
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in
patients with Homozygous Familial Hypercholesterolemia (HoFH).